113 related articles for article (PubMed ID: 1862551)
1. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study.
Fountzilas G; Skarlos D; Pavlidis NA; Makrantonakis P; Tsavaris N; Kalogera-Fountzila A; Giannakakis T; Beer M; Kosmidis P
Tumori; 1991 Jun; 77(3):232-6. PubMed ID: 1862551
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
3. High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.
Fountzilas G; Skarlos D; Katsohis C; Pavlidis N; Giannakakis T; Bafaloukos D; Fahantidis E; Klouvas G; Beer M; Kosmidis P
Med Pediatr Oncol; 1995 Jan; 24(1):23-8. PubMed ID: 7526143
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
[TBL] [Abstract][Full Text] [Related]
5. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
[TBL] [Abstract][Full Text] [Related]
6. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.
Fountzilas G; Athanassiades A; Giannakakis T; Briasoulis E; Bafaloukos D; Kalogera-Fountzila A; Onienaoum A; Kalofonos H; Pectasides D; Andreopoulou E; Bamia C; Kosmidis P; Pavlidis N; Skarlos D
Ann Oncol; 1997 Dec; 8(12):1213-20. PubMed ID: 9496386
[TBL] [Abstract][Full Text] [Related]
8. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.
Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T
Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459
[TBL] [Abstract][Full Text] [Related]
10. A weekly schedule of epirubicin in pretreated advanced breast cancer.
Barni S; Archili C; Lissoni P; Paolorossi F; Crispino S; Tancini G
Tumori; 1993 Feb; 79(1):45-8. PubMed ID: 8497922
[TBL] [Abstract][Full Text] [Related]
11. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer.
Zamagni C; Martoni A; Ercolino L; Baroni M; Tanneberger S; Pannuti F
J Chemother; 1991 Apr; 3(2):126-9. PubMed ID: 1875232
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
[TBL] [Abstract][Full Text] [Related]
14. Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.
Stöger H; Bauernhofer T; Kasparek AK; Schmid M; Moser R; Ploner F; Derstvenscheg E; Kuss I; Wilders-Truschnig M; Steindorfer P
Cancer Chemother Pharmacol; 1994; 34(1):75-8. PubMed ID: 8174206
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer.
Stöger H; Schmid M; Bauernhofer T; Moser R; Ploner F; Derstvenscheg E; Kasparek AK; Kuss I; Wilders-Truschnig M; Lackner C
Oncology; 1994; 51(6):518-22. PubMed ID: 7970497
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
[TBL] [Abstract][Full Text] [Related]
19. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
20. Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
Kümmel S; Thomas A; Paepke S; Schwarz M; Heinrich G; Wetzel A; Elling D; Kohls A; Lichtenegger W; Blohmer JU
Acta Oncol; 2005; 44(3):248-54. PubMed ID: 16076697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
